The EPS estimate of Flex Pharma, Inc. (NASDAQ:FLKS) for quarter ended 2016-09-30 is $-0.74.
EPS projections 7 and 30 days ago were $-0.74 and $-0.74 respectively. Analysts projected $-0.74 and $-0.74 respectively as EPS 60 and 90 days ago. The projections shows a change of 0% from estimates of 7-days ago.
The EPS revisions up and down count in the preceding 7 days were 0 and 0 respectively. The count of bullish revisions in earnings in the last 1-month, 60, 90 and 120 days were 0, 0, 1 and 1.
The count of bearish revisions of EPS in the last 1-month, 60, 90 and 120 days were 0, 0, 1 and 1.
The count of EPS revisions bullish and bearish in the last 18 days were 1 and 1 respectively.
The EPS projection prior to the release of actual report for the period closed 1 is $-0.74 on basis of 3 EPS estimates. As on 2016-05-04, the reported EPS was $-0.61, showing a surprise of $-0.02 or -3.39%. It showed a standard deviation of 0.25.
Quarterly Sales Estimates
The arithmetic mean of released annual sales estimates for Flex Pharma, Inc. (NASDAQ:FLKS) is $0.263 and the median is $0.21. The estimate is calculated by 3 analysts for the fiscal 2016.
The highest annual estimate is $0.5 and the lowest estimate is $0.079. The standard deviation of given annual sales estimates is 0.215%.
As many as 3 and 3 analysts have increased and decreased sales estimate, respectively in last seven days. It shows a percentage change of 0% from the past week.
Almost 3 and 3 analysts have increased and decreased sales estimate, respectively in last one month. It shows a percentage change of 0% from last month.
The number of analysts who have upped and decreased their sales projections in the last one-quarter is 3 and 3 respectively. The change in the estimate from last quarter is -38.837%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...